PMID- 32957900
OWN - NLM
STAT- MEDLINE
DCOM- 20220204
LR  - 20221207
IS  - 2212-3873 (Electronic)
IS  - 1871-5303 (Linking)
VI  - 21
IP  - 8
DP  - 2021
TI  - Resistance Exercise Versus Aerobic Exercise Combined with Metformin Therapy in 
      the Treatment of type 2 Diabetes: A 12-Week Comparative Clinical Study.
PG  - 1531-1536
LID - 10.2174/1871530320999200918143227 [doi]
AB  - BACKGROUND: Both exercise and metformin are used to control blood glucose levels 
      in patients with type 2 diabetes mellitus (T2DM), while no previous studies have 
      investigated the effect of resistance exercise combined with metformin versus 
      aerobic exercise with metformin in T2DM patients. OBJECTIVES: This study was 
      conducted to compare the effects of resistance exercise combined with metformin 
      versus aerobic exercise with metformin in T2DM patients. METHODS: A total of 
      fifty-seven T2DM patients with a mean age of 46.2+/-8.3 years were randomized to 
      three study groups; each group included nineteen patients. The first group 
      conducted a resistance exercise program (REP, 50-60% of 1RM, for 40-50 min) 
      combined with metformin, the second group conducted an aerobic exercise program 
      (AEP, 50-70% maxHR, for 40-50 min) combined with metformin, and the third group 
      received only metformin without exercise intervention (Met group). The study 
      program was conducted thrice weekly for consecutive twelve weeks. Fasting blood 
      glucose (FBG), glycated hemoglobin (HbA1c), homeostatic model assessment of 
      insulin resistance (HOMA-IR), and maximal oxygen uptake (VO2max) were evaluated 
      before and after study intervention. RESULTS: Significant differences were 
      reported after the 12-week intervention inter-groups in the outcome variables 
      (p<0.05). FBG, HbA1c, HOMA-IR, and VO2max improved significantly in the REP group 
      (p<0.001) and also in the AEP group (p=0.016, p=0.036, p=0.024, and p=0.019 
      respectively) while the Met group showed an only significant reduction in FBG 
      (p=0.049), and non-significant changes in HbA1c, HOMA-IR, and VO2max (p>0.05). 
      REP group achieved greater improvements than AEP group (FBG, p=0.034; HbA1c%, 
      p=0.002; HOMA-IR, p<0.001; and VO2max, p=0.024). CONCLUSION: Both resistance and 
      aerobic exercise programs combined with metformin are effective in controlling 
      T2DM. Resistance exercise combined with metformin is more effective than aerobic 
      exercise combined with metformin in the treatment of T2DM.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Abdelbasset, Walid Kamal
AU  - Abdelbasset WK
AD  - Department of Health and Rehabilitation Sciences, College of Applied Medical 
      Sciences, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia.
LA  - eng
GR  - 2020/03/11877/Prince Sattam bin Abdulaziz University/
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United Arab Emirates
TA  - Endocr Metab Immune Disord Drug Targets
JT  - Endocrine, metabolic & immune disorders drug targets
JID - 101269157
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Insulin)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Adult
MH  - Blood Glucose/metabolism
MH  - Combined Modality Therapy
MH  - Diabetes Mellitus, Type 2/blood/*therapy
MH  - Exercise/*physiology
MH  - Exercise Therapy/methods
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Insulin/blood
MH  - Male
MH  - Metformin/*therapeutic use
MH  - Middle Aged
MH  - *Resistance Training
MH  - Saudi Arabia
OTO - NOTNLM
OT  - Type 2 diabetes mellitus
OT  - aerobic exercise
OT  - glucose oxidation
OT  - insulin resistance
OT  - maximal oxygen uptake.
OT  - metformin
OT  - resistance exercise
EDAT- 2020/09/23 06:00
MHDA- 2022/02/05 06:00
CRDT- 2020/09/22 05:30
PHST- 2020/04/04 00:00 [received]
PHST- 2020/08/11 00:00 [revised]
PHST- 2020/08/12 00:00 [accepted]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2022/02/05 06:00 [medline]
PHST- 2020/09/22 05:30 [entrez]
AID - EMIDDT-EPUB-110086 [pii]
AID - 10.2174/1871530320999200918143227 [doi]
PST - ppublish
SO  - Endocr Metab Immune Disord Drug Targets. 2021;21(8):1531-1536. doi: 
      10.2174/1871530320999200918143227.